Table 2. Distribution of Anthracycline, Mitoxantrone, and Chest Radiotherapy Exposures by Cancer Diagnosis.
| Diagnosis | Participants, No. (%)a | |||||
|---|---|---|---|---|---|---|
| Doxorubicin (n = 9330) | Daunorubicin (n = 4433) | Epirubicin (n = 342) | Idarubicin (n = 241) | Mitoxantrone (n = 265) | Chest Radiotherapy (n = 6240) | |
| Leukemia | 2498 (28.6) | 3865 (44.2) | 41 (0.5) | 233 (2.7) | 210 (2.4) | 1126 (12.9) |
| Lymphoma | 2637 (48.1) | 545 (10.0) | 96 (1.8) | 5 (0.1) | 54 (1.0) | 2547 (46.5) |
| Brain tumor | 25 (0.5) | 1 (0.0) | 1 (0.0) | 3 (0.1) | NA | 1156 (23.9) |
| Neuroblastoma | 737 (36.4) | 7 (0.3) | 41 (0.2) | NA | NA | 325 (16.1) |
| Kidney tumor | 945 (37.1) | 3 (0.1) | 125 (4.9) | NA | 1 (0.1) | 567 (22.3) |
| Soft-tissue sarcoma | 700 (34.9) | 3 (0.1) | 67 (3.3) | NA | NA | 187 (9.3) |
| Bone tumor | 1729 (80.4) | 4 (0.2) | 1 (0.0) | NA | NA | 269 (12.5) |
| Other malignant neoplasm | 59 (9.3) | 5 (0.8) | 7 (1.1) | NA | NA | 63 (9.9) |
Abbreviation: NA, not applicable.
a
Percentages shown are the proportions of exposures across each row (ie, by diagnosis).